Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10815985 | 0.81 | CYP4F2 (0.41) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL10398085 | 0.80 | GAA (0.38) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL10398506 | 0.80 | GAA (0.38) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL16415357 | 0.80 | TSHR (0.42) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL11199031 | 0.79 | GAA (0.40) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL11202548 | 0.78 | GAA (0.39) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL11202739 | 0.77 | GAA (0.39) | NR4A2L3MBTL1HSD17B10POLBBRD4 | |
| SCHEMBL10814009 | 0.75 | KMT2A (0.35) | KDM4ENR4A2L3MBTL1HSD17B10POLB | |
| SCHEMBL16611515 | 0.75 | ALDH1A1 (0.40) | KDM4EHSD17B10POLBGAATSHR | |
| SCHEMBL11195432 | 0.73 | GAA (0.36) | KDM4ENR4A2L3MBTL1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2007017264-A2 | PYRROLOPYRIDINEDERIVATIVES AS MODULATORS OF THE CANNABINOID RECEPTOR FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | KDM4E 2054/4885NR4A2 750/4885L3MBTL1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.